EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune-related encephalitis after immune checkpoint inhibitor therapy

Monica W Buckley, Aanika Balaji Warner iD, Julie Brahmer, Laura C Cappelli, William H Sharfman, Ephraim Fuchs, Hyunseok Kang, Patrick M Forde, Douglas E Gladstone, Richard Ambinder, Ronan J Kelly, Evan J Lipson iD und 8 weitere

The Oncologist · 17.01.2025 · 30 (1)

DOI: 10.1093/oncolo/oyae186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 26.07.2024. Verfasst von Monica W Buckley und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Encephalitis, Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen, EMD Serono, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but can trigger immune-related encephalitis. We report one of the largest case series of patients with immune-related encephalitis and review of the literature.

Methods

Retrospective series of patients with immune-related encephalitis and literature review.

Results

Fourteen patients with cancer treated with ICI (50% combination therapy) developed immune-related encephalitis. Diagnostic testing revealed cerebral spinal fluid (CSF) lymphocytic pleocytosis (85%) and elevated protein (69%), abnormal brain magnetic resonance imaging(MRI) (33%) or brain FDG-PET (25%), electroencephalogram (EEG) abnormalities (30%), and autoantibodies (31%). Encephalitis treatment included: corticosteroids (86%), intravenous immunoglobulin (IVIg) (36%), plasmapheresis (7%), and rituximab (29%). There were no deaths and 12 patients had significant recovery, although long-term complications were observed. All patients discontinued ICI. Longitudinal follow-up demonstrated anti-cancer response to ICI at 3 months (85%) and 6 months post-ICI initiation (77%). A literature review identified 132 patients with immune-related encephalitis. Most were treated with PD-1 inhibitors (18% combination). Common abnormalities included elevated CSF protein (84%) or pleocytosis (77%), abnormal brain MRI (65%), or autoantibodies (47%). Nearly all were treated with corticosteroids, many required additional therapy with IVIg (26%) or rituximab (12%). Most patients had clinical improvement (81%) but a minority (10%) had a clinical relapse after completing corticosteroid taper. ICIs were resumed in 7 patients (5%), with relapse in 3. Conclusions and relevance Immune-related encephalitis is treatable and improves with corticosteroids in most cases but may require additional immunosuppression. Re-emergence of encephalitis is rare and does not typically result in adverse outcomes, and this should be considered in neurological immune-related adverse event management guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsEncephalitisNeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and over

Stichwörter der Autor:innen

autoimmunecancerencephalitisimmune checkpoint

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
  • Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA 22903, United States.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
  • Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States.
  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
  • Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, United States.

ORCID-Profile: Aanika Balaji Warner, Evan J Lipson, John C Probasco

Förderung

  • Biogen
  • EMD Serono
  • NCI NIH HHS
  • AstraZeneca
  • Amgen
  • AbbVie
  • Celgene
  • Bristol-Myers Squibb

Zitieren

APA

Buckley, M. W., Balaji Warner, A., Brahmer, J., Cappelli, L. C., Sharfman, W. H., Fuchs, E., Kang, H., Forde, P. M., Gladstone, D. E., Ambinder, R., Kelly, R. J., Lipson, E. J., Gojo, I., Lee, E. J., Johnson, T. P., Saidha, S., Llinas, R., Ostrow, L. W., Naidoo, J., & Probasco, J. C. (2025). Immune-related encephalitis after immune checkpoint inhibitor therapy. The Oncologist, 30(1). https://doi.org/10.1093/oncolo/oyae186

Vancouver

Buckley MW, Balaji Warner A, Brahmer J, Cappelli LC, Sharfman WH, Fuchs E, et al. Immune-related encephalitis after immune checkpoint inhibitor therapy. The Oncologist. 2025;30(1). doi:10.1093/oncolo/oyae186

BibTeX
@article{Buckley2025,
  author = {Buckley, Monica W and Balaji Warner, Aanika and Brahmer, Julie and Cappelli, Laura C and Sharfman, William H and Fuchs, Ephraim and Kang, Hyunseok and Forde, Patrick M and Gladstone, Douglas E and Ambinder, Richard and Kelly, Ronan J and Lipson, Evan J and Gojo, Ivana and Lee, Edward J and Johnson, Tory P and Saidha, Shiv and Llinas, Rafael and Ostrow, Lyle W and Naidoo, Jarushka and Probasco, John C},
  title = {Immune-related encephalitis after immune checkpoint inhibitor therapy},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {1},
  doi = {10.1093/oncolo/oyae186}
}
Kostenlos starten →